Lyell Immunopharma, Inc. (LYEL)
$14.53-$0.08 (-0.55%) Today
Lynn Seely - OfficerLynn Seely - OfficerLyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 14 | 16,087 | $246K |
| Grant or award | 7 | 64,750 | |
| Other acquisition / disposition | 4 | 225,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
57 Form 4 filings on record, the earliest from Nov 1, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Gary K. Lee - Officer | Open-market sale | Common Stock | 1,671 | $23.39 | $39K | |
| Stephen J. Hill - Officer | Grant or award | Common Stock | 4,000 | $0.00 | - | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 109 | $23.12 | $3K | |
| Stephen J. Hill - Officer | Grant or award | Option (right to buy) | 65,000 | $0.00 | - | |
| Gary K. Lee - Officer | Grant or award | Common Stock | 4,000 | $0.00 | - | |
| Gary K. Lee - Officer | Open-market sale | Common Stock | 147 | $23.12 | $3K | |
| Gary K. Lee - Officer | Grant or award | Option (right to buy) | 50,000 | $0.00 | - | |
| Lynn Seely - Officer | Grant or award | Common Stock | 20,000 | $0.00 | - | |
| Lynn Seely - Officer | Open-market sale | Common Stock | 438 | $23.12 | $10K | |
| Lynn Seely - Officer | Grant or award | Option (right to buy) | 155,000 | $0.00 | - | |
| Mark A. Meltz - Officer | Grant or award | Option (right to buy) | 50,000 | $0.00 | - | |
| Veronica Sanchez Bulis - Officer | Grant or award | Common Stock | 8,750 | $0.00 | - | |
| Veronica Sanchez Bulis - Officer | Open-market sale | Common Stock | 254 | $23.12 | $6K | |
| David Shook - Officer | Grant or award | Option (right to buy) | 50,000 | $0.00 | - | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 95 | $16.12 | $2K | |
| Gary K. Lee - Officer | Open-market sale | Common Stock | 138 | $16.16 | $2K | |
| Veronica Sanchez Bulis - Officer | Open-market sale | Common Stock | 239 | $16.10 | $4K | |
| Lynn Seely - Officer | Open-market sale | Common Stock | 412 | $16.11 | $7K | |
| Stephen J. Hill - Officer | Grant or award | Option (right to buy) | 75,000 | $0.00 | - | |
| Lynn Seely - Officer | Grant or award | Option (right to buy) | 175,000 | $0.00 | - | |
| Gary K. Lee - Officer | Grant or award | Option (right to buy) | 68,000 | $0.00 | - | |
| Lynn Seely - Officer | Grant or award | Common Stock | 40,000 | $0.00 | - | |
| Lynn Seely - Officer | Open-market sale | Common Stock | 7,257 | $10.54 | $77K | |
| Stephen J. Hill - Officer | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 1,004 | $10.54 | $11K | |
| Charles W. Newton - Officer | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Charles W. Newton - Officer | Open-market sale | Common Stock | 1,453 | $10.54 | $15K | |
| Gary K. Lee - Officer | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Gary K. Lee - Officer | Open-market sale | Common Stock | 1,453 | $10.54 | $15K | |
| Lynn Seely - Officer | Open-market sale | Common Stock | 391 | $10.53 | $4K | |
| Lynn Seely - Officer | Open-market sale | Common Stock | 406 | $10.34 | $4K | |
| Charles W. Newton - Officer | Open-market sale | Common Stock | 131 | $10.53 | $1K | |
| Charles W. Newton - Officer | Open-market sale | Common Stock | 136 | $10.34 | $1K | |
| Gary K. Lee - Officer | Open-market sale | Common Stock | 131 | $10.53 | $1K | |
| Gary K. Lee - Officer | Open-market sale | Common Stock | 136 | $10.34 | $1K | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 91 | $10.53 | $958 | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 94 | $10.34 | $972 | |
| Otis W. Brawley | Grant or award | Option (right to buy) | 130,000 | $0.00 | - | |
| William Jl Rieflin | Grant or award | Option (right to buy) | 130,000 | $0.00 | - | |
| Otis W. Brawley | Open-market purchase | Common Stock | 35,640 | $11.20 | $20K | |
| Sumant Ramachandra | Grant or award | Option (right to buy) | 260,000 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 57 LYEL filings on record.
Lyell Immunopharma, Inc. (LYEL) had 25 insider filings in the last 90 days, with the most recent on 2026-08-25. The full record for LYEL runs to 57 Form 4 filings, the earliest from 2024-11-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of LYEL were filed in the last 90 days. 3 purchases are on record for this company.
14 insider sales of LYEL were filed in the last 90 days, totaling $246K.
This page tracks LYEL Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LYEL to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
